Literature DB >> 23280491

Intronic SH2D1A mutation with impaired SAP expression and agammaglobulinemia.

Mike Recher1, Ari J Fried, Michel J Massaad, Hye Young Kim, Michela Rizzini, Francesco Frugoni, Jolan E Walter, Divij Mathew, Hermann Eibel, Christoph Hess, Silvia Giliani, Dale T Umetsu, Luigi D Notarangelo, Raif S Geha.   

Abstract

X-linked lymphoproliferative (XLP) disease is a primary immunodeficiency syndrome associated with the inability to control Epstein-Barr virus (EBV), lymphoma, and hypogammaglobulinemia. XLP is caused by mutations in the SH2D1A gene, which encodes the SLAM-associated protein (SAP), or in the BIRC4 gene, which encodes the X-linked inhibitor of apoptosis protein (XIAP). Here we report a patient with recurrent respiratory tract infections and early onset agammaglobulinemia who carried a unique disease-causing intronic loss-of-function mutation in SH2D1A. The intronic mutation affected SH2D1A gene transcription but not mRNA splicing, and led to markedly reduced level of SAP protein. Despite undetectable serum immunoglobulins, the patient's B cells replicated and differentiated into antibody producing cells normally in vitro.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23280491      PMCID: PMC3742382          DOI: 10.1016/j.clim.2012.11.007

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  24 in total

1.  Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets.

Authors:  Andrew D Hislop; Umaimainthan Palendira; Alison M Leese; Peter D Arkwright; Pierre S Rohrlich; Stuart G Tangye; H Bobby Gaspar; Arjan C Lankester; Alessandro Moretta; Alan B Rickinson
Journal:  Blood       Date:  2010-07-19       Impact factor: 22.113

2.  Correlation of mutations of the SH2D1A gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease.

Authors:  J Sumegi; D Huang; A Lanyi; J D Davis; T A Seemayer; A Maeda; G Klein; M Seri; H Wakiguchi; D T Purtilo; T G Gross
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

3.  Immunoglobulin class and subclass deficiencies prior to Epstein-Barr virus infection in males with X-linked lymphoproliferative disease.

Authors:  H L Grierson; J Skare; J Hawk; M Pauza; D T Purtilo
Journal:  Am J Med Genet       Date:  1991-09-01

4.  Epstein-Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP).

Authors:  O Brandau; V Schuster; M Weiss; H Hellebrand; F M Fink; A Kreczy; W Friedrich; B Strahm; C Niemeyer; B H Belohradsky; A Meindl
Journal:  Hum Mol Genet       Date:  1999-12       Impact factor: 6.150

5.  Genomic organization and characterization of mouse SAP, the gene that is altered in X-linked lymphoproliferative disease.

Authors:  C Wu; J Sayos; N Wang; D Howie; A Coyle; C Terhorst
Journal:  Immunogenetics       Date:  2000-08       Impact factor: 2.846

6.  Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency).

Authors:  Jana Pachlopnik Schmid; Danielle Canioni; Despina Moshous; Fabien Touzot; Nizar Mahlaoui; Fabian Hauck; Hirokazu Kanegane; Eduardo Lopez-Granados; Ester Mejstrikova; Isabelle Pellier; Lionel Galicier; Claire Galambrun; Vincent Barlogis; Pierre Bordigoni; Alain Fourmaintraux; Mohamed Hamidou; Alain Dabadie; Françoise Le Deist; Filomeen Haerynck; Marie Ouachée-Chardin; Pierre Rohrlich; Jean-Louis Stephan; Christelle Lenoir; Stéphanie Rigaud; Nathalie Lambert; Michèle Milili; Claudin Schiff; Helen Chapel; Capucine Picard; Geneviève de Saint Basile; Stéphane Blanche; Alain Fischer; Sylvain Latour
Journal:  Blood       Date:  2010-11-30       Impact factor: 22.113

Review 7.  X-linked lymphoproliferative syndromes: brothers or distant cousins?

Authors:  Alexandra H Filipovich; Kejian Zhang; Andrew L Snow; Rebecca A Marsh
Journal:  Blood       Date:  2010-07-26       Impact factor: 22.113

8.  SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease.

Authors:  Reza Sharifi; Joanna C Sinclair; Kimberly C Gilmour; Peter D Arkwright; Christine Kinnon; Adrian J Thrasher; H Bobby Gaspar
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

9.  Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP.

Authors:  Umaimainthan Palendira; Carol Low; Anna Chan; Andrew D Hislop; Edwin Ho; Tri Giang Phan; Elissa Deenick; Matthew C Cook; D Sean Riminton; Sharon Choo; Richard Loh; Frank Alvaro; Claire Booth; H Bobby Gaspar; Alessandro Moretta; Rajiv Khanna; Alan B Rickinson; Stuart G Tangye
Journal:  PLoS Biol       Date:  2011-11-01       Impact factor: 8.029

10.  SH2D1A regulates T-dependent humoral autoimmunity.

Authors:  Jonathan D Hron; Liron Caplan; Andrea J Gerth; Pamela L Schwartzberg; Stanford L Peng
Journal:  J Exp Med       Date:  2004-07-19       Impact factor: 14.307

View more
  3 in total

1.  Severe XLP Phenotype Caused by a Novel Intronic Mutation in the SH2D1A Gene.

Authors:  B Tóth; B Soltész; E Gyimesi; G Csorba; Á Veres; Á Lányi; G Kovács; L Maródi; M Erdős
Journal:  J Clin Immunol       Date:  2014-12-10       Impact factor: 8.317

Review 2.  Gene hunting in the genomic era: approaches to diagnostic dilemmas in patients with primary immunodeficiencies.

Authors:  Craig Platt; Raif S Geha; Janet Chou
Journal:  J Allergy Clin Immunol       Date:  2013-10-05       Impact factor: 10.793

Review 3.  Familial hemophagocytic lymphohistiocytosis: when rare diseases shed light on immune system functioning.

Authors:  Elena Sieni; Valentina Cetica; Yvonne Hackmann; Maria Luisa Coniglio; Martina Da Ros; Benedetta Ciambotti; Daniela Pende; Gillian Griffiths; Maurizio Aricò
Journal:  Front Immunol       Date:  2014-04-16       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.